Erratum (DOI:10.1016/j.healun.2009.05.007);Utility of Routine Immunofluorescence Staining for C4d in Cardiac Transplant Recipients

Journal of Heart and Lung Transplantation

Volumn 28, Issue 8, 2009, Pages 776-780

  Gupta, Sachin ^a   Mitchell, Joshua D ^a   Lavingia, Bhavna ^b   Ewing, Gene E ^b   Feliciano, M Nicholas ^b   Kaiser, Patricia A ^c   Ring, W Steves ^b   Stastny, Peter ^b   Patel, Parag C ^a   Markham, David W ^a   Mammen, Pradeep P A ^a   DiMaio, J Michael ^b   Drazner, Mark H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c St Paul University Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COMPLEMENT COMPONENT C4D; COTRIMOXAZOLE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HEART GRAFT; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTOSIS; PRIORITY JOURNAL;

EID: 67650720291     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.07.012     Document Type: Erratum

References (19)

1. Michaels P.J., Espejo M.L., Kobashigawa J., et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 22 (2003) 58-69
2. Stastny P., Lavingia B., Fixler D.E., Yancy C.W., and Ring W.S. Antibodies against donor human leukocyte antigens and the outcome of cardiac allografts in adults and children. Transplantation 84 (2007) 738-745
3. Crespo-Leiro M.G., Veiga-Barreiro A., Domenech N., et al. Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): incidence, management, and the value of C4d for diagnosis. Am J Transplant 5 (2005) 2560-2564
4. Uber W.E., Self S.E., Van Bakel A.B., and Pereira N.L. Acute antibody-mediated rejection following heart transplantation. Am J Transplant 7 (2007) 2064-2074
5. Patel J.K., and Kobashigawa J.A. Should we be doing routine biopsy after heart transplantation in a new era of anti-rejection?. Curr Opin Cardiol 21 (2006) 127-131
6. Taylor D.O., Yowell R.L., Kfoury A.G., Hammond E.H., and Renlund D.G. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 19 (2000) 518-521
7. Kfoury A.G., Stehlik J., Renlund D.G., et al. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. J Heart Lung Transplant 25 (2006) 1277-1282
8. Stewart S., Winters G.L., Fishbein M.C., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24 (2005) 1710-1720
9. Kfoury A.G., Hammond M.E., Snow G.L., et al. Early screening for antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant 26 (2007) 1264-1269
10. Rodriguez E.R., Skojec D.V., Tan C.D., et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant 5 (2005) 2778-2785
11. Fedson S.E., Daniel S.S., and Husain A.N. Immunohistochemistry staining of C4d to diagnose antibody-mediated rejection in cardiac transplantation. J Heart Lung Transplant 27 (2008) 372-379
12. Rosenberg P.B., Vriesendorp A.E., Drazner M.H., et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 24 (2005) 1327-1331
13. Rosenbaum D.H., Adams B.C., Mitchell J.D., et al. Effects of early steroid withdrawal after heart transplantation. Ann Thorac Surg 82 (2006) 637-644 discussion 644
14. Gupta S., Mitchell J.D., Markham D.W., et al. High incidence of cytomegalovirus disease in D+/R- heart transplant recipients shortly after completion of 3 months of valganciclovir prophylaxis. J Heart Lung Transplant 27 (2008) 536-539
15. Holt D.B., Liapis H., Mohanakumar T., et al. Complement fragment C4d and C3d deposition in pediatric heart recipients with a positive crossmatch. J Heart Lung Transplant 27 (2008) 1073-1078
16. Chantranuwat C., Qiao J.H., Kobashigawa J., Hong L., Shintaku P., and Fishbein M.C. Immunoperoxidase staining for C4d on paraffin-embedded tissue in cardiac allograft endomyocardial biopsies: comparison to frozen tissue immunofluorescence. Appl Immunohistochem Mol Morphol 12 (2004) 166-171
17. Smith R.N., Brousaides N., Grazette L., et al. C4d deposition in cardiac allografts correlates with alloantibody. J Heart Lung Transplant 24 (2005) 1202-1210
18. Reed E.F., Demetris A.J., Hammond E., et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 25 (2006) 153-159
19. Behr T.M., Feucht H.E., Richter K., et al. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J Heart Lung Transplant 18 (1999) 904-912